Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 7.2 of its best-in-class ADMET Predictor™ molecular property prediction software.

Dr. Robert Clark, director of cheminformatics at Simulations Plus, said, “The latest release of ADMET Predictor contains updated cytochrome P450 kinetics models that are seamlessly integrated into the recently released GastroPlus™ Version 9.0, enhancing our synergy between predicted properties and PBPK simulations. It also contains two new models related to human liver microsome (HLM) stability, an experiment that is routinely run on newly synthesized compounds in the pharmaceutical industry.”

Dr. Michael Lawless, business development manager for cheminformatics solutions, added, “Our cytochrome P450 kinetics models have been improved by additional data curation. The updated models illustrate our commitment to providing the best predictive models in the industry. The new HLM intrinsic clearance model was built using literature data from roughly 1,500 molecules published by pharmaceutical industry scientists. Thus, the model’s chemistry space is highly relevant to lead discovery.”

John DiBella, vice president for marketing and sales, added, “ADMET Predictor enjoys an outstanding reputation for speed and accuracy, providing chemists with a tool that lets them predict over 150 properties of molecules from just their structure drawings. This capability means chemists can filter through huge numbers of virtual molecules and eliminate the majority based on high ADMET Risk™ without the need to synthesize and test them. The cost and time savings realized from high-quality property predictions is substantial.”